A groundbreaking stem cells project to treat Parkinson's disease Researchers are making significant head-way in the fight to treat Parkinson's Disease. We have the latest on Stem-cell research.. Happening right here in San Diego. Our biotechnology reporter and 2 Parkinson's patients tell us how they are raising money for their own experimental stem cell treatment, in partnership with researchers from The Scripps Research Institute and health care workers from Scripps Clinic. Watch us on Cox 114, AT T U-Verse 17/1017HD or http://www.uttv.com/watch-live/ Follow us on Facebook http://www.facebook.com Tweet us on twitter - twitter.com/uttvsd Find us on Instagram - utsandiegotv And, please subscribe to our channel! By: U-T San Diego … Continue reading →

ROCKVILLE, Md., March 14, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, was listed as the 15th most influential person in the stem field in the "Top 50 Global Stem Cell Influencers," published by Total BioPharma, a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) The list is the result of a global stem cell community survey to determine the most influential individuals in the field, including researchers, and business and government leaders. About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, in February 2013, and has submitted recommended Phase II trial protocol to the FDA. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Companys three ongoing stem cell clinical trials in the United States and Europe has authorized the Company to move forward with enrolling and treating the patients in the next cohort of each of the trials. Per each trials protocol, the first patient of cohort 3 will be injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. This represents a fifty percent increase in the dose of RPE cells as compared to the previously treated cohort of patients. The first patients treated at this escalated dose will be evaluated, with interim DSMB review after six weeks, at which time the determination to continue treating additional patients at this dosage will be made. Additionally, the DSMB has authorized the Company to proceed with treating patients in the two U.S. trials as part of additional cohorts recently approved by the FDA. In particular, the FDA approved the addition of two new cohorts of four patients each one cohort for each of the Stargardts Macular Dystrophy (SMD) and dry … Continue reading →